THERAPY DOSSIER · th-57344f655956

Syngeneic spleen cells or bone marrow cells

Biologic · Cell therapy; no ChEMBL drug entity applicable.

Evidence & regulatory context

Mechanism: Cell therapy; no ChEMBL drug entity applicable.
Target: Not recorded
Injury models: Radiation
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 1

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT00000647 ↗NAcompleted

Zidovudine, interferon-alfa and recombinant CD4-IgG with transplantation of syngeneic bone marrow and peripheral blood lymphocytes in HIV infection

HIV Infections

Enrolment: 6 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 6965356 ↗1980Mixed findings

Immunodepression, a noncontributor to radiation-induced leukemogenesis of the RFM mouse.

MouseRadiationRFMFemale50 x 10^6 cellsImmediately following X-irradiation

Model: Single acute whole-body exposure to 300 R of X-rays

Spleen cells restored immunocompetence more rapidly but did not protect against radiation-induced thymic lymphoma, whereas bone marrow cells did not accelerate immune recovery yet markedly reduced mortality.

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…